Stavudine delivery in an extended release formulation: Will it provide the right in vivo pharmacokinetics — Some key observations

Main Article Content

Editor AJP


Saravanakumar et al, (2010) have performed an
extensive study to enable the delivery of stavudine
in a once daily extended release formulation.[1] The
in vitro evaluation has been performed with multiple
formulation options to enable the selection of the
right formulation system that renders once-a-day
delivery of stavudine, ensuring that zero order release
is maintained during the entire duration. As evidenced
by the generated data, the recommended formulation
(F9), appears to release approximately 4% of the drug
load every hour leading to a complete release of the
stavudine drug load by 24 hours.


Download data is not yet available.

Article Details

How to Cite
AJP, E. (2014). Stavudine delivery in an extended release formulation: Will it provide the right in vivo pharmacokinetics — Some key observations. Asian Journal of Pharmaceutics (AJP), 5(1).


Saravanakumar M, Venkateshwaramurthy N, Dhachinamoorthi D,

Perumal P. Extended release matrix tablets of stavudine: Formulation

and in vitro evaluation. Asian J Pharma 2010;4:219-23.

Zhou L, Kaul S, Liu-Kreyche P, Tran SB, Espina RR, Warrack BM, et al.

Disposition of [1'-(14)C]stavudine after oral administration to humans.

Drug Metab Dispos 2010;38:655-66.

Monif T, Tippabhotla SK, Garg M, Singla AK Comparative bioavailability/

bioequivalence of two different stavudine 40 mg capsule formulations:

A randomized, 2-way, crossover study in healthy volunteers under

fasting condition. Int J Clin Pharmacol Ther 2007;45:469-74.

Narang VS, Lulla A, Malhotra G, Purandare S. Bioequivalence evaluation

of two marketed brands of stavudine 40 mg capsules in healthy human

South African volunteers. Pharmacol Res 2004;50:511-6.

Waclawski AP, Sinko PJ. Oral absorption of anti-acquired immune

deficiency syndrome nucleoside analogues. 2. Carrier-mediated

intestinal transport of stavudine in rat and rabbit preparations. J Pharm

Sci 1996;85:478-85.

Hasegawa T, Juni K, Saneyoshi M, Kawaguchi T.Intestinal absorption

and first-pass elimination of 2', 3'-dideoxynucleosides following oral

administration in rats. Biol Pharm Bull 1996;19:599-603.

Ghosh A, Bhaumik UK, Bose A, Mandal U, Gowda V, Chatterjee B, et al.

Extended release dosage form of glipizide: Development and validation

of a level A in vitro-in vivo correlation. Biol Pharm Bull 2008;31:1946-51.

Dutta S, Qiu Y, Samara E, Cao G, Granneman GR. Once-a-day extendedrelease

dosage form of divalproex sodium III: Development and

validation of a Level A in vitro-in vivo correlation (IVIVC). J Pharm Sci


Etropolski MS, Okamoto A, Shapiro DY, Rauschkolb C. Dose conversion

between tapentadol immediate and extended release for low back pain.

Pain Physician 2010;13:61-70.

Jullien V, Raïs A, Urien S, Dimet J, Delaugerre C, Bouillon-Pichault M,

Rey E, Pons G, Blanche S, Tréluyer JM. Age-related differences in the

pharmacokinetics of stavudine in 272 children from birth to 16 years:

A population analysis. Br J Clin Pharmacol.2007;64:105-9.

Most read articles by the same author(s)

> >>